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golensin (O-DMA) (OR = 0.76; 95% CI 0.61–0.92). Multivari-
ate analysis did not attenuate this finding (OR = 0.74; 95% 
CI 0.61–0.90).  Conclusions: This first analysis of the rela-
tionship between phytoestrogens and frailty revealed an 
inverse association between urinary O-DMA levels and 
frailty in women. However, the number of frail women was 
low. Although this finding may be confounded or biased, 
it seems worthwhile to intensify research on the potential 
preventive effects of O-DMA.  © 2013 S. Karger AG, Basel 
 Introduction 
 Frailty is characterized by a decreased resistance to 
stress due to cumulative declines in multiple interrelated 
physiologic systems  [1, 2] . This results in an increased 
risk of falls, disability, hospitalization, institutionaliza-
tion, and mortality  [2] . Frailty is the consequence of im-
pairment of multiple subsystems, such as sarcopenia  [3] , 
nutritional deficiencies  [4] , hormonal declines  [5] , or in-
flammation  [6] , and knowledge of the pathophysiological 
mechanisms of frailty remains limited.
 Key Words 
 Frailty · Phytoestrogens · National Health and Nutrition 
Examination Survey · Elderly women 
 Abstract 
 Background/Aims: A deficit of various hormones during 
the process of aging and/or a heightened inflammatory 
state may be causally linked to the development of frail-
ty. Phytoestrogens as weak estrogens, antioxidants, and 
anti-inflammatory agents may counteract this process. 
 Methods: In a cross-sectional study including two cycles
of the National Health and Nutrition Examination Survey 
(NHANES, i.e. 1999–2002), logistic regression was used to 
analyze the association between urinary concentrations of 
isoflavones and lignans and frailty in 600 females aged 50 
years or older (median age 66.5 years). Participants were 
classified as ‘frail’ (meeting 3 or more of the 5 frailty crite-
ria), ‘prefrail’ (meeting 1 or 2 of the criteria), or ‘robust’ 
(meeting none of the criteria). Four percent were frail.  Re-
sults: For all of the phytoestrogens considered, the unad-
justed OR were lower than 1 but generally not statistically 
significant aside from the association with O-desmethylan-
 Received: July 29, 2013 
 Accepted after revision: October 15, 2013 
 Published online: December 7, 2013 
 Monika Eichholzer, MD 
 Division of Cancer Epidemiology and Prevention 
 Institute of Social and Preventive Medicine, University of Zurich 
 Hirschengraben 84, CH–8001 Zurich (Switzerland) 
 E-Mail monika.eichholzer   @   ifspm.uzh.ch 
 © 2013 S. Karger AG, Basel
0250–6807/13/0634–0269$38.00/0 
 www.karger.com/anm 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.3
4.
16
3 
- 1
2/
9/
20
13
 2
:0
4:
23
 P
M
 Eichholzer  /Richard  /Walser-Domjan  /
Linseisen  /Rohrmann  
 
Ann Nutr Metab 2013;63:269–276
DOI: 10.1159/000356453
270
 The most widely used definition of frailty is the one by 
Fried et al.  [2] , which includes unintentional weight loss, 
self-reported exhaustion, poor grip strength, slow walk-
ing speed, or low physical activity. Frailty is rarely ob-
served in the absence of (subclinical) chronic disease. Un-
intentional weight loss may be the consequence of cata-
bolic processes in the course of an underlying disease or 
it may be related to low energy and nutrient intakes. Ac-
cordingly, the characteristics of 65- to 79-year-old wom-
en becoming frail during follow-up in the Women’s 
Health Initiative study were: high and low body weight, 
smoking, depression, cardiovascular disease (CVD), dia-
betes, and chronic obstructive pulmonary disease  [7] . 
Furthermore, in the InCHIANTI study  [8] more than half 
of the frail participants had insufficient intakes of energy, 
protein, calcium, iron, zinc and the vitamins A, D, E, C, 
and/or folate. In this cross-sectional study a low energy 
intake was associated with exhaustion, and a low nutrient 
score of proteins and vitamins was associated with weak-
ness.
 However, frailty is not a unidirectional process  [9] . It 
is possible to recover from frailty to prefrailty and non-
frailty conditions, respectively  [10] . This makes the adop-
tion of preventive measures attractive. Accordingly, trials 
investigating the effect of hormone replacement therapy 
(HRT) in women on muscle mass and strength suggest a 
direct relationship with levels of plasma estradiol, but 
their results remain conflicting  [11] . There is even evi-
dence that usual-dose estrogen may accelerate muscle 
loss  [12] and that higher levels of endogenous estradiol 
are directly associated with frailty  [3] . It is therefore of 
interest to examine the effect of natural, weak estrogens 
on the risk of frailty in elderly women, without the health 
risks associated with the use of HRT.
 Phytoestrogens are naturally occurring plant constit-
uents found in many human foodstuffs. As their name 
implies, phytoestrogens may act as weak estrogens  [13] . 
In addition, they may act as antioxidants and anti-in-
flammatory agents  [14] . There are three main groups of 
phytoestrogens, i.e. isoflavones (in soybeans and other 
legumes), lignans (in flaxseed and berries), and coumes-
tans (in soybean sprouts)  [13] . The major soy isofla-
vones are daidzin and genistin, the glycoside conjugates 
of daidzein and genistein  [15] . After ingestion, daidzein 
can be metabolized by gut bacteria into diverse com-
pounds such as equol and O-desmethylangolensin (O-
DMA). About 30–35% of the Western population and 
up to 60% of vegetarians and Asians possess the ability 
to produce equol, but these percentages vary between 
studies, depending, among other things, on the urine 
equol concentration used as the cutoff and the equol in-
take via milk products  [16–19] . Equol is 100 times more 
estrogenic than daidzein  [20] . Several animal products 
such as cheese, eggs, and milk also contain equol  [18, 
21] . The major human lignans are enterolactone and en-
terodiol, formed from plant precursors by the gut mi-
croflora  [13] .
 So far, the health effects of phytoestrogens have of-
ten been studied by measuring the dietary intake of 
these compounds by study participants. However, mea-
surement of the concentration of phytoestrogens in 
urine takes into account interindividual variations in 
microbial synthesis  [22] and is independent of errors 
due to imprecise dietary assessments and databases. To 
determine whether frailty, based on a modified index 
of Fried et al.  [2; see also 23] , is associated with urinary 
phytoestrogen concentrations of isoflavones, lignans, 
genistein, daidzein, equol, equol of equol producers, O-
DMA, enterolactone, and enterodiol, we used the data 
of women aged 50 years or older from the National 
Health and Nutrition Survey (NHANES) 1999–2002. 
To our knowledge, this is the first study to investigate 
the association between these urinary phytoestrogen 
levels and frailty.
 Methods 
 Study Design 
 NHANES is an on-going cross-sectional study representative 
of the population of the USA, which is being conducted by the 
National Center for Health Statistics (NCHS). Data are released 
for 2 successive years (i.e. 1999/2000, 2001/2002, etc.). NHANES 
is a program of studies designed to assess the health and nutri-
tional status of adults and children in the USA. The survey is 
unique in that it combines interviews and physical examina-
tions.
 The NHANES interview includes demographic, socioeconom-
ic, dietary, and health-related questions. The examination compo-
nent consists of medical, dental, and physiological measurements, 
as well as laboratory tests administered by highly trained medical 
personnel. All data are anonymized.
 The sample for the survey is selected to represent US popula-
tions of all ages. A complex, multistage, probability sampling de-
sign is used to select participants representative of the civilian, 
noninstitutionalized US population. To produce reliable statistics, 
NHANES oversamples individuals aged 60 years or older, African-
Americans, and Hispanics.
 Participants (n = 21,004) were available from the 1999/2000 
and 2001/2002 NHANES cycles. After exclusion of participants 
younger than 50 years, our sample consisted of 4,983 individuals. 
In a further step, all men were excluded, leaving 2,551 women in 
our data set. Of these women, 617 had available data on urinary 
phytoestrogen measurements. After defining frailty variables, fi-
nally 600 women were included in our analyses.
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 The NHANES study protocols are in accordance with the 
guidelines put forth in the Declaration of Helsinki, and all proce-
dures involving human subjects were approved by NCHS Research 
Ethics Review Board. Written informed consent was obtained 
from all subjects.
 Measurement of Urinary Phytoestrogen Concentration 
 Urine specimens were processed, stored, and shipped to the 
Division of Environmental Health Laboratory Sciences, National 
Center for Environmental Health, Centers for Disease Control and 
Prevention, for analysis [24]. Vials were stored under appropriate 
frozen (–20   °   C) conditions until shipment to the National Center 
for Environmental Health for testing. An HPLC-MS/MS method 
was used to determine urinary phytoestrogen concentrations in 
NHANES  [12] . The methods were adapted, which resulted in im-
proved selectivity, sensitivity, and precision for the quantitative 
detection of phytoestrogens in human urine and serum. The meth-
od uses enzymatic deconjugation of the phytoestrogens followed 
by solid-phase extraction and reverse-phase HPLC to resolve the 
analytes. The phytoestrogens are detected using a Sciex API III 
heated nebulizer-atmospheric pressure chemical ionization (HN-
APCI) interface coupled with MS/MS. The following phytoestro-
gens were measured in both NHANES cycles (1999/2000 and 
2001/2002): daidzein, genistein, equol, O-DMA, enterodiol, and 
enterolactone. In our analyses, isoflavones were represented by 
daidzein, genistein, equol, and O-DMA. Lignans consisted of en-
terodiol and enterolactone.
 The creatinine concentration was analyzed using a Jaffé rate 
reaction with a CX3 analyzer (Beckmann Instruments, Brea, Calif., 
USA)  [25] . In our analyses, we used creatinine to standardize uri-
nary phytoestrogen concentrations. Phytoestrogen concentrations 
were expressed as micrograms per gram of creatinine.
 Assessment of Frailty 
 We based our analyses on the frailty score developed by Fried 
et al.  [2] , which was modulated to the data available in NHANES 
III by Wilhelm-Leen et al.  [23] and to the data available in NHANES 
1999–2002. This adapted score comprised the following 5 items: 
(1) low body weight for height, defined as a BMI  ≤ 18.5; (2) slow 
walking, defined as the slowest quintile by sex in a timed 20-ft walk; 
(3) weakness, defined as present if participants answered ‘some 
difficulty’, ‘much difficulty’, or ‘unable to do’ when asked how 
much difficulty they have ‘lifting or carrying something as heavy 
as ten pounds (like a sack of potatoes or rice)’; (4) exhaustion, de-
fined as present if participants answered ‘some difficulty’, ‘much 
difficulty’, or ‘unable to do’ when asked how much difficulty they 
have ‘walking from one room to the other on the same level’, and 
(5) low physical activity, defined as present if participants an-
swered ‘less active’ when asked: ‘Compared with most women your 
age, would you say that you are more active, less active or about 
the same?’
 In our analysis we included participants with valid information 
on at least 3 of the 5 frailty symptoms. One item was missing for 
60 women, and 2 items were missing for 115 women. In total, all 
of the participants with 1 or 2 components missing emerged as 
belonging to the subgroup ‘robust’ (see below).
 Women meeting 3 or more of the 5 criteria were classified as 
‘frail’, those with 1 or 2 criteria were classified as ‘prefrail’, and 
those meeting none of the criteria were classified as ‘robust’. In ad-
dition, the frailty variable was dichotomized into ‘frails’ (3 or more 
frailty criteria) versus ‘nonfrails’ (0–2 frailty criteria) for the pur-
poses of our analyses  [2, 23] .
 Other Explanatory Variables 
 Age, sex, race/ethnicity, poverty income ratio (PIR), cigarette 
smoking, and use of HRT were assessed using a questionnaire. 
Weight was measured to the nearest 0.01 kg using an electronic 
digital scale while the participant was wearing a paper shirt and 
paper pants and foam slippers. Height was measured to the nearest 
0.1 cm using a stadiometer. The BMI was calculated as the weight 
in kilograms divided by the square of the height in meters. A self-
reported history of congestive heart failure, coronary heart disease, 
heart attack, or stroke was used to define prevalent CVD, and a 
self-reported history of a diagnosis of cancer (other than nonmel-
anoma skin cancer) was used to define prevalent cancer. Partici-
pants were considered to be diabetic if they reported a history of a 
diagnosis of diabetes or were users of insulin or diabetic medica-
tion. A self-reported history of hypertension was assessed if the 
participants had been told at least twice by a doctor that they had 
hypertension and/or if the participants took medication.
 Statistical Analysis 
 Analyses were performed using STATA version 11 (Stata Corpo-
ration, College Station, Tex., USA), and p < 0.05 was considered sta-
tistically significant (two-sided tests). Sampling weights were applied 
according NHANES guidelines to produce estimates that were rep-
resentative of the noninstitutionalized, civilian US population  [26] .
 We used medians to compare phytoestrogen levels in the cat-
egories of frailty (robust, prefrail, and frail) and percentages for 
demographic variables. Differences between groups were evalu-
ated using a univariate t statistic or χ 2 test, respectively. All sig-
nificance tests were two-sided using p < 0.05 as the level of statisti-
cal significance.
 Frailty was dichotomized into frail and nonfrail (prefrail and ro-
bust) for logistic regression, which was used to calculate OR and 95% 
CI. We did combine prefrails with robusts and not with frails because 
we were not able to fully distinguish between robusts and prefrails 
due to missing data. Creatinine-standardized phytoestrogen concen-
trations were continuous variables. Besides the unadjusted model, we 
adjusted in a first model for age ( ≥ 50–59, 60–69, 70–79, and >80; 
equal results were found when we considered age as a continuous 
variable) and race/ethnicity (non-Hispanic black, non-Hispanic 
white, Mexican-American, and other). With the multivariable mod-
el, we wanted to evaluate potential confounders that influence frailty. 
Thus, besides age and race/ethnicity, we also included the PIR [which 
is the proportion of the self-reported family income to the US census-
based poverty threshold value for each calendar year adjusted for 
inflation and the age of the family reference person (a PIR value of 1 
or greater indicates an income above the poverty level, whereas a PIR 
value below 1 indicates poverty)], smoking history (former, current, 
or never), current HRT (yes or no), and chronic diseases, i.e. CVD, 
hypertension, diabetes, and cancer. Furthermore, we performed a 
subanalysis for equol concentration in equol producers. Equol pro-
ducers were defined as having an equol concentration over the detec-
tion limit. Moreover, we conducted a sensitivity analysis comparing 
the prevalence of frailty symptoms and the distribution of frailty 
scores in the women of our sample (n = 600) with those in women 
aged 50 years or older not included in our sample (n = 1,951) to 
evaluate differences between these two groups of women.
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 Results 
 Tables 1 and  2 summarize the biochemical, lifestyle, 
and clinical variables of the participants with data on uri-
nary phytoestrogen concentrations and frailty. Of the 600 
women (unweighted n) included in the present analysis, 
64.4% belonged to the category robust, 31.6% belonged to 
the category prefrail, and 4.0% belonged to the category 
frail. Comparing our sample to the nonincluded women 
in the same age range (n = 1,951), 70.1% belonged to the 
category robust, 27.1% belonged to the category prefrail, 
and 2.9% belonged to the category frail. The prevalence 
of frailty symptoms in the nonincluded sample was dis-
tributed as follows: weakness, 43.3%; slow walking, 19.3%; 
exhaustion, 18.3%; low physical activity, 20.1%, and low 
BMI, 1.6% (see  table 1 for a comparison with the included 
women).
 In relation to phytoestrogens, a higher percentage of 
frail women versus prefrail and robust women had a 
somehow lower urine concentration of lignans, equol, O-
DMA, enterodiol, and enterolactone. The opposite was 
true for isoflavones, daidzein, and genistein. Among all 
women, 63.6% were equol producers. The equol concen-
tration in frail equol producers was slightly higher than 
in robust women.
 Moreover, a higher percentage of frails versus pre-
frails/robusts were HRT users. A history of CVD, diabe-
tes, and hypertension, but not of cancer, was more often 
noted among frail women than prefrail and robust wom-
en (for statistically significant differences, see the p values 
in  table 2 ).
 Table 3 presents the associations between phytoestro-
gen concentrations and frailty. Unadjusted OR were be-
low 1 for all phytoestrogens considered, but neither was 
statistically significant, with the exception of O-DMA 
(OR = 0.76; 95% CI 0.61–0.92). Models adjusting for age 
and race/ethnicity revealed similar results, again with a 
significantly reduced risk of frailty with increasing O-
DMA urinary levels (OR = 0.76; 95% CI 0.62–0.92). The 
latter finding was not attenuated in multivariate analysis 
(OR = 0.74; 95% CI 0.61–0.90). Considering age as a con-
tinuous variable did not affect the results.
 Discussion 
 To the best of our knowledge, this is the first study to 
investigate the association between urinary phytoestrogen 
concentrations and frailty. In our cross-sectional study, 
representative of noninstitutionalized US women aged 50 
years or older, 64.4% were robust, 31.6% were prefrail, and 
4.0% were frail. The low percentage of frails observed in 
the present analysis most probably reflects the rather low 
age group considered. Furthermore, some of the women 
may not yet have experienced menopause (no data on 
menopausal status were available), which is of importance 
for musculoskeletal health  [27] . In addition, there may 
be an underestimation of the proportion of frails since 
NHANES requires participants to come in for examina-
tion. A considerable number of frails might have been 
physically unable to participate, and not all of the frail 
women might have used the alternative of a home exami-
nation. Accordingly, the prevalence of frailty in the com-
munity-dwelling population of Western countries has 
been estimated to be about 6–20% using various defini-
tions of frailty  [28, 29] . In comparison, in the first study 
estimating the prevalence of frailty in Taiwan, 4.9% of se-
niors aged 65–103 years were frail, 40% were prefrail, and 
55.1% were nonfrail (no criterion of frailty)  [28] , i.e. the 
prevalence of frailty was lower than in Western countries. 
Moreover, we confirmed previous observations showing 
a higher risk of frailty for subjects with chronic disease 
such as diabetes  [30] , hypertension  [31] , or a history of 
CVD  [32] . The urinary phytoestrogen concentrations in 
the present study were comparable to those in previous 
studies in the US population  [20] but lower than, for ex-
ample, those in people living in Japan or Vietnam  [33] .
 We observed no significant association between frailty 
and urinary levels of isoflavones, lignans, genistein, en-
terodiol, enterolactone, daidzein, or equol in women. 
There was one exception: increasing urinary O-DMA lev-
Table 1. Prevalence of frailty symptoms and distribution of frailty 
scores (unweighted n = 600) in women aged 50 years or older from 
NHANES 1999 – 2002
na %b
Frailty score [23]
0 371 64.4
1 150 22.2
2 57 9.4
3 – 5 22 4.0
Frailty score components
Weakness 175 33.7
Slow walking 121 28.3
Exhaustion 56 11.6
Low physical activity 99 16.1
Low BMI 9 1.8
 a Unweighted. b Weighted.
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els were associated with significantly lower odds of frailty 
in the multivariate analysis.
 O-DMA is an intestinal bacterial metabolite of daid-
zein. Not all individuals harbor bacteria capable of me-
tabolizing daidzein to O-DMA, i.e. individuals can be 
classified as O-DMA producers and nonproducers. About 
80–95% of individuals of soy-consuming populations are 
O-DMA producers. Factors that may influence an indi-
vidual’s ability to produce O-DMA include the composi-
tion of the gut microflora, endogenous hormones, host 
genetics, and nonmodifiable host factors (e.g. decreasing 
levels with increasing age)  [20, 34, 35] . O-DMA is less 
structurally similar to 17b-estradiol than its precursor 
compound daidzein and may exhibit different biological 
actions than daidzein.
 Several biological actions of O-DMA have been ob-
served in vitro, e.g. effects on cancer cells, binding to es-
trogen, androgen, and progesterone receptors, osteoclast 
formation, influencing immunological markers, and rad-
ical scavenging activity  [36] . Furthermore, Low et al.  [37] 
Table 2.  Age-standardized baseline characteristics by frailty status in women aged 50 years or older from NHANES 
1999 – 2002
Fraila  Prefrailb and robustc p value
median Q1 Q3 medi an Q1 Q3
Phytoestrogens, μg/g creatinine
Isoflavonesd 116.8 28.4 423.6 104.1 46.2 339.9 0.033
Lignanse 394.2 107.6 766.0 476.6 192.7 1,038.7 0.145
Daidzein 62.6 14.7 214.7 48.3 16.4 169.6 0.057
Equol 5.0 2.4 11.8 7.8 3.7 17.3 0.024
Equol among equol producers 14.1 6.0 38 11.9 6.7 24.1 0.046
Genistein 46.2 11.7 115.8 25.0 10.0 89.6 0.081
O-DMA 1.3 0.4 7.4 2.9 0.6 19.8 0.021
Enterodiol 40.1 10.5 100.0 44.0 18.3 93.9 0.569
Enterolactone 316.9 58.7 417.2 402.4 133.3 944.6 0.003
Age, years 69 57 75 66 60 75 0.525
BMI 30.8 25.4 35.8 28.1 24.0 32.3 0.091
% %
Race 0.885g
Non-Hispanic white 74.4 76.6
Non-Hispanic black 11.3 10.1
Mexican-American 6.6 3.6
Other 7.8 9.8
PIR 0.176g
Below poverty 16.3 15.2
At or above poverty 81.8 73.6
Missing 1.9 11.2
Smoking history 0.81g
Current smoker 20.9 18.6
Former smoker 23.8 21.8
Never 55.4 60.0
HRT users 37.3 27.2 0.532
Chronic diseasesf
History of diabetes 32.6 10.4 0.057
History of hypertension 59.9 46.4 0.176
History of cancer 10.4 14.8 0.506
History of CVD 35.6   11.5  0.004
 Values are weighted and age-standardized, except for medians. a Participants meeting 3 or more of the 5 cri-
teria of the frailty score. b Participants meeting 1 or 2 of the criteria. c Participants meeting none of the criteria.
d Daidzein, equol, genistein, and O-DMA. e Enterodiol and enterolactone. f Self-reported. g χ2 test.
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stratified analyses of plasma sex hormones by presence
or no presence of detectable urinary O-DMA concen-
trations in women aged 45–74 years who participated 
in EPIC-Norfolk. O-DMA-producing women had 6%
higher plasma estradiol concentrations after adjustment 
for potential confounding factors. Overall, O-DMA could 
affect the risk of frailty via various mechanisms. It is not 
just a marker for aging as adjustment for age did not sub-
stantially modify the effect estimate in our study.
 The interpretation of the inverse association of O-
DMA with frailty in women is complex. Firstly, the cross-
sectional study design does not allow for establishment of 
the temporal sequence of events. Frailty could result from 
low O-DMA concentrations, but frailty is also known for 
an increased risk of malnutrition and this could affect the 
dietary intake of soy products or products containing soy. 
The major sources of phytoestrogens in the US diet are 
doughnuts, pancakes, waffles, and bread, all of which 
contain added soy  [20] . Secondly, O-DMA may be seen 
as an indicator of high soy consumption, and other bioac-
tive compounds and nutrients in soy may play a role in 
the prevention of frailty  [8, 38–42] . Thirdly, there is some 
evidence that the intestinal microflora of O-DMA pro-
ducers may transform additionally polyphenolic dietary 
compounds, such as quercetin and kaempferol, which 
may reveal specific biological effects  [36] . Finally, people 
with a high soy food intake, such as Asian people or veg-
etarians, may consume a more balanced diet than Amer-
icans consuming soy mainly through fortified foods, such 
as pancakes and doughnuts  [41] . An unbalanced diet in 
our study population could be one of the reasons why we 
did not observe associations between most phytoestro-
gens and frailty in the present study. Furthermore, it is 
possible that, because this was a low-soy-consumption 
population, isoflavonoide and other phytoestrogen levels 
were too low or there was insufficient variation in the ex-
posure to detect associations. Moreover, in the present 
study, the urine samples for the determination of phy-
toestrogen levels were spot urines, and measurements in 
spot urines may not be representative of the habitual nu-
tritional intake of phytoestrogens. However, in a previous 
analysis of NHANES III data, urinary and serum levels of 
phytoestrogens showed a good correlation (daidzein r = 
0.72)  [43] . In addition, given the low prevalence of frails, 
the power of this study is limited and further studies are 
warranted to illuminate the associations of phytoestro-
gens with frailty. On the other hand, the comparison of 
the women of our sample with women of the same age 
range not included in our sample showed that the distri-
bution of frailty prevalence was similar.
 Conclusion 
 Even though the observed negative association between 
O-DMA and frailty in women of the present study may be 
the result of various confounders, it may be worthwhile to 
intensify research on the potential preventive effects of O-
DMA. It should be taken into consideration that a low uri-
nary concentration of O-DMA may be the result of a low 
intake of soy and/or of not being able to harbor the neces-
sary intestinal microflora to produce these compounds.
Table 3.  Associations between phytoestrogen concentrations and frailty in women aged 50 years or older from 
NHANES 1999 – 2002
Phytoestrogens, μg/g creatinine Unadjusted Age, race/ethnicity Multivariable adjusteda
OR (95% CI) OR (95% CI) OR (95% CI)
Isoflavonesb 0.79 (0.56 – 1.12) 0.80 (0.57 – 1.12) 0.82 (0.62 – 1.08)
Lignansc 0.71 (0.47 – 1.07) 0.70 (0.46 – 1.06) 0.68 (0.46 – 1.01)
Daidzein 0.83 (0.61 – 1.15) 0.84 (0.61 – 1.15) 0.86 (0.66 – 1.12)
Genistein 0.95 (0.71 – 1.27) 0.95 (0.71 – 1.28) 0.97 (0.77 – 1.21)
O-DMA 0.76 (0.62 – 0.92) 0.76 (0.62 – 0.92) 0.75 (0.61 – 0.92)
Enterodiol 0.81 (0.51 – 1.27) 0.82 (0.51 – 1.31) 0.79 (0.52 – 1.22)
Equol among equol producers 0.87 (0.55 – 1.36) 0.89 (0.59 – 1.34) 0.97 (0.64 – 1.46)
Equol 0.85 (0.61 – 1.18) 0.86 (0.62 – 1.19) 0.88 (0.63 – 1.23)
Enterolactone 0.81 (0.61 – 1.07) 0.81 (0.61 – 1.07) 0.80 (0.60 – 1.07)
 Frailty was dichotomized into nonfrail and frail. a Adjusted for age, race, PIR, HRT, smoking history, and 
chronic diseases (CVD, hypertension, diabetes, and cancer). b Daidzein, equol, genistein, and O-DMA. c Entero-
diol and enterolactone.
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